Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 14/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.45 |
| ▸ | PER2 | O15055 | 1/20 | 0.41 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.41 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28194834 | 0.72 | FFAR4 (0.44) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL28207011 | 0.72 | FFAR4 (0.44) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL19673967 | 0.72 | FFAR4 (0.44) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL8157650 | 0.72 | BRD4 (0.50) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL28064793 | 0.70 | TRPA1 (0.44) | FFAR4FFAR1 | |
| SCHEMBL28828092 | 0.70 | NFE2L2 (0.42) | — | |
| SCHEMBL9255195 | 0.69 | CACNA1H (0.43) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL3587960 | 0.69 | FFAR4 (0.42) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL23733163 | 0.69 | FFAR4 (0.42) | FFAR4FFAR1PER2CRY1CRY2 | |
| SCHEMBL26048160 | 0.69 | FFAR4 (0.42) | FFAR4FFAR1PER2CRY1CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238155-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238155-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | PYGL, HMOX2, MB | FFAR4 1427/4885FFAR1 945/4885PER2 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.